Best-Link
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Best-Link - overview
Established
2021
Location
Shanghai, -, China
Primary Industry
Pharmaceuticals
About
Based in Shanghai, China and founded in 2021, Shanghai Best-Link Bioscience LLC, trading as Best-Link, focuses on the development of novel nano-conjugate drugs and precise nano-drug delivery platforms based on advanced conjugation technology and nanotechnology to develop innovative drugs for precision cancer treatment and tumor immunotherapy. It has submitted more than 10 invention patent applications through independent research and development as of 2023. In December 2025, Best-Link raised a series B funding from new investors Hongcheng Investment Management, Beijing Sun-Novo Pharmaceutical Research, Yonghua Capital, Casstar Capital, TEDA Venture Capital and returning investor Lapam Capital. The company is dedicated to creating a drug coupling platform and a drug precision delivery platform based on advanced drug linkage technology to develop innovative drugs for oncology precision therapy and oncology immunotherapy.
The company's revenue is generated by providing nano-conjugate drugs.
Current Investors
Lapam Capital, Hyfinity Investments, TigerYeah Capital
Primary Industry
Pharmaceuticals
Sub Industries
Biopharmaceuticals, Oncology/Cancer Treatment, Specialty Pharmaceuticals, Pharmaceutical Research & Development
Website
www.bestlinkbio.com/
Verticals
Manufacturing
Company Stage
Series B
Total Amount Raised
Subscriber access only
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.